Our xTAG® and MultiCode™-RTx Technologies serve a wide range of clinical applications, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.
Read More
Our xMAP® Technology and its flexible, open-architecture design is used in a wide variety of applications, from academic and clinical research to biodefense and clinical diagnostics.
Read More
Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® technology. Click here to start the conversation now.
Learn More
The Faces of Luminex: Jimm Chengary, Global Product Management
The area of bloodstream infection is a key focus for Luminex. Our VERIGENE® platform helps clinical lab teams to rapidly diagnose sepsis, track antibiotic resistance markers, and assist physicians in getting patients on the most appropriate therapy sooner. Overseeing this area is Jimm Chengary, who joined Luminex earlier this year and is based in our Chicago office. The DePaul University graduate holds a bachelor’s degree in finance and accounting as well as an MBA in marketing and finance.
Continue Reading >
xMAP Technology makes up the basis of Luminex’s core business. This flexible technology is centered on the use of Luminex xMAP Microspheres.
Watch more videos >
September 11
Luminex Corporation Declares Third Quarter Cash Dividend
September 6
Luminex Corporation to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
August 6
Luminex Corporation Reports Second Quarter 2018 Financial Results
July 13
Luminex Corporation Second Quarter Earnings Release Scheduled for August 6, 2018
June 13
Luminex Initiates Clinical Trials for VERIGENE® II Gastrointestinal Assay
Microbe UK
21-23 September
Sheffield, UK
World Vaccine Congress
29-31 October
Lisbon, Portugal
xMAP® Connect Amsterdam
6-7 November
Amsterdam, Netherlands
